Peroxisome proliferator-activated receptors (PPARs) inhibit lipopolysaccharide (LPS)-primed release of high mobility group box 1 (HMGB1), a late proinflammatory mediator, but the underlying molecular mechanism is not completely understood. In this study, we demonstrated that the inhibition of HMGB1 release by PPAR-δ and -γ is associated with the deacetylase activity of SIRT1. Ligand-activated PPAR-δ and -γ inhibited LPS-primed release of HMGB1, concomitant with elevation in SIRT1 expression and promoter activity. These effects were significantly reduced in the presence of small interfering (si)RNAs against PPAR, indicating that PPAR-δ and -γ are involved in both HMGB1 release and SIRT1 expression. In addition, modulation of SIRT1 expression and activity by siRNA or chemicals correspondingly influenced the effects of PPARs on HMGB1 release, suggesting a mechanism in which SIRT1 modulates HMGB1 release. Furthermore, we showed for the first time that HMGB1 acetylated in response to LPS or p300/CBP-associated factor (PCAF) is an effective substrate for SIRT1, and that deacetylation of HMGB1 is responsible for blockade of HMGB1 release in macrophages. Finally, acetylation of HMGB1 was elevated in mouse embryonic fibroblasts from SIRT1-knockout mice, whereas this increase was completely reversed by ectopic expression of SIRT1. These results indicate that PPAR-mediated upregulation of SIRT1 modulates the status of HMGB1 acetylation, which, in turn, has a critical role in the cellular response to inflammation through deacetylation-mediated regulation of HMGB1 release. Cell Death and Disease (2014) 5, e1432; doi:10.1038/cddis.2014.406; published online 2 October 2014
Peroxisome proliferator-activated receptors (PPARs) are a family of transcription factors belonging to the nuclear receptor superfamily, whose members regulate numerous genes via ligand-dependent transcriptional activation and repression. [1] [2] [3] Three different members of the PPAR family have been identified, encoded by separate genes: PPAR-α (NR1C1), PPAR-β/δ (NR1C2), and PPAR-γ (NR1C3). 3 PPARs possess a central DNA-binding domain that recognizes a specific DNA sequence, the PPAR-response element (PPRE), in the promoter regions of their target genes. 4 PPARs heterodimerize with retinoid X receptors (RXR), which are also members of the nuclear receptor superfamily. Transcriptional regulation of target genes by PPARs is achieved through the binding of these PPAR-RXR heterodimers to the PPRE, yielding pleiotropic effects on the regulation of lipid and glucose metabolism, as well as cellular differentiation and proliferation. 1, 3, 5 PPAR activators exert anti-inflammatory activities in various cell types by interfering with proinflammatory transcription-factor signaling pathways. [6] [7] [8] Furthermore, we recently showed that ligand-activated PPAR-γ counteracts the release of high mobility group box 1 (HMGB1) primed by lipopolysaccharide (LPS), thereby improving survival in an LPS-induced animal model of endotoxemia. 9 Therefore, PPARs may represent a target for the treatment of diseases associated with inflammation, 6 and a deeper understanding of the anti-inflammatory activities governed by PPARs may lead to realization of this therapeutic potential.
HMGB1 is a ubiquitously expressed molecule that functions as a structural protein of chromatin. 10 This protein is typically located in the nucleus, where it binds to the minor groove of DNA, promoting the assembly of site-specific DNA-binding factors and having roles in transcription. 11, 12 In addition to its nuclear roles, HMGB1 also functions as an inflammatory cytokine when released from necrotic cells or actively secreted from stressed cells. 13, 14 Recent studies have shown that the posttranslational modification status of HMGB1 is related to its translocation and secretion in inflammatory cells, in which it shuttles from the nucleus to the cytoplasm in a process governed by hyperacetylation, phosphorylation, and methylation. [15] [16] [17] In particular, HMGB1 is extensively acetylated upon activation by LPS, resulting in localization of the protein to the cytosol. 15 This trans-localization is accompanied by accumulation of cytosolic HMGB1, leading to secretion through a vesicle-mediated secretory pathway in monocytes and macrophages. 15, 18 Furthermore, extracellular HMGB1 is a late mediator of sepsis and acts as a key regulator in acute and chronic inflammation, suggesting that this protein represents a novel target for the treatment of inflammatory disorders. 19, 20 SIRT1, a NAD + -dependent class III protein deacetylase, is a mammalian orthologue of yeast silent information regulator 2 that acts on a wide range of histones and nonhistone substrates. 21 SIRT1 has emerged as a critical regulator of metabolic and physiological processes including aging, energy metabolism, and stress resistance; it acts by coordinating complex gene expression programs through deacetylation of histones, transcription factors, and coregulators. 22, 23 SIRT1 also has an important role in modulating the development and progression of inflammation by deacetylating histones and critical transcription factors such as nuclear factor kappa B (NF-κB), activation protein 1 (AP-1), forkhead box O transcription factors, and PPAR-γ coactivator-1α, resulting in transcriptional repression of various inflammation-related genes. [24] [25] [26] Furthermore, several lines of evidence indicate that a reduction in the level and activity of SIRT1 are closely correlated with chronic inflammatory conditions. 27, 28 Although the details of SIRT1-dependent anti-inflammatory activities are gradually becoming clearer, many unanswered questions remain. Meanwhile, recent reports have shown that the activation of PPARs by specific ligands increases SIRT1 expression both in vitro and in vivo.
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On the basis of these findings, we hypothesized that the inhibition of HMGB1 release by PPARs may be partly attributed to the upregulation of SIRT1. In this report, we show that ligand-activated PPAR-δ and -γ modulate LPSprimed release of HMGB1 through SIRT1-mediated deacetylation during the cellular response to inflammation.
Results
Ligand-activated PPARs inhibit LPS-induced release of HMGB1. In our previous study, in vitro and in vivo analysis using specific ligands of PPARs revealed that these receptors inhibit LPS-primed release of HMGB1. 9 To confirm our previous findings, we first performed detailed biochemical analyses using PPAR ligands in RAW 264.7 cells. As shown in Figure 1a , the level of released HMGB1 was increased upon LPS treatment, but this increase was suppressed in the presence of PPAR ligands, suggesting that PPARs are involved in the inhibition of LPS-induced HMGB1 release. Among the PPAR ligands, GW501516 (a specific ligand of PPAR-δ) and rosiglitazone (a specific ligand of PPAR-γ) were more effective than WY-14643 (a specific ligand of PPAR-α). In contrast to the secreted levels, neither LPS nor PPAR ligands affected the expression levels of intracellular HMGB1.
GW501516-or rosiglitazone-mediated inhibition of HMGB1 release is dependent on PPAR-δ or -γ, respectively. To examine the roles of PPAR-δ and -γ in GW501516-or rosiglitazone-mediated inhibition of LPS-induced HMGB1 release, we examined the effects of GW501516 and rosiglitazone in RAW 264.7 cells treated with small interfering (si)RNA against PPAR-δ or -γ. The levels of PPAR-δ and -γ in cells were reduced upon transfection with the corresponding siRNAs, whereas control siRNAs comprising a pool of nonspecific sequences had no effect on the levels of either protein (Supplementary Figure 1) . As expected, siRNA against PPAR-δ or -γ suppressed the inhibitory effects of GW501516 or rosiglitazone, respectively, indicating that PPAR-δ and -γ directly regulate LPS-induced HMGB1 release in RAW 264.7 cells (Figures 1b and c) .
Acetylation is involved in the regulation of LPS-induced HMGB1 release. Because hyperacetylation of HMGB1 enables nuclear shuttling of the protein into the cytoplasm and its subsequent release from LPS-stimulated After incubation in serum-free medium for 24 h, the cells were stimulated with LPS for 24 h in the presence or absence of GW501516 (b) or rosiglitazone (c). Equal volumes of conditioned media or aliquots of cell lysates were subjected to western blotting for determination of HMGB1 levels. An image analyzer was used to quantitate band intensity, and the ratios of HMGB1 to Ponceau S are shown. The results are expressed as means ± S.E.M. (n = 3). **Po0.01 compared with the untreated group; monocytes, 15 we examined the relationship between the levels of HMGB1 acetylation and HMGB1 release in RAW 264.7 cells treated with LPS. As shown in Figure 2 , HMGB1 acetylation was elevated in cells treated with LPS, as revealed by detection of lysyl-acetylated HMGB1 with antiacetyl-lysine antibody in immunoprecipitates obtained using anti-HMGB1 antibody. This increase was attenuated in the presence of resveratrol, an activator of SIRT1, which is a class III deacetylase; 21 inversely, blockade of SIRT1 using siRNA or a specific inhibitor potentiated LPS-induced acetylation of HMGB1. In concordance with HMGB1 acetylation status, LPS-primed release of HMGB1 was also influenced by the modulation of SIRT1 expression and activity. These results indicate that SIRT1-mediated regulation of HMGB1 acetylation is a critical step in LPS-induced release of HMGB1.
Deacetylation by SIRT1 mediates the effects of PPAR-δ and -γ in the inhibition of LPS-primed HMGB1 release. To further investigate the molecular mechanisms underlying the PPAR-δ/γ-mediated inhibition of HMGB1 release, we analyzed the levels of acetylated HMGB1 by co-immunoprecipitation with anti-HMGB1 antibody in whole-cell lysates and conditioned media. In RAW 264.7 cells exposed to LPS, the levels of acetylated HMGB1 were increased in a time-dependent manner. A parallel pattern was also observed in the cell culture supernatants (Supplementary Figure 2) . The level of acetylated HMGB1 in the whole-cell lysates peaked 6 h after incubation with LPS, and then declined to the basal level ( Figure 3a ). This increase in acetylated HMGB1 was significantly reduced by GW501516 or rosiglitazone, suggesting that PPAR-δ and -γ are involved in the LPS-induced deacetylation of HMGB1 ( Figure 3b ).
We next examined the effects of siRNA-mediated SIRT1 knockdown on the levels of HMGB1 acetylation induced by LPS. As shown in Figures 3c and d, SIRT1 siRNA reversed the GW501516-or rosiglitazone-mediated suppression of HMGB1 acetylation in LPS-treated cells, suggesting that PPAR-δ and -γ modulate LPS-induced HMGB1 acetylation via SIRT1.
Ligand-activated PPAR-δ and -γ upregulate SIRT1 expression in RAW 264.7 cells. To further examine the roles of SIRT1 in the regulation of HMGB1 release, we investigated the effects of PPAR-δ and -γ on the expression of SIRT1. When cells were treated with GW501516 or rosiglitazone, the levels of SIRT1 mRNA and protein were increased in a time-dependent manner (Figures 4a and b ). Significant elevation in the level of SIRT1 mRNA was detected at times as early as 0.5-1 h, with protein levels lagging slightly behind (Figures 4a and b) .
To verify the roles of PPAR-δ and -γ in the upregulation of SIRT1, we examined the effect of GW501516 or rosiglitazone in cells treated with siRNA against PPAR-δ or -γ. siRNAmediated downregulation of PPAR-δ or -γ suppressed the GW501516-or rosiglitazone-induced expression of SIRT1, suggesting that PPAR-δ and -γ are involved in the regulation of SIRT1 expression (Figures 4c and d) .
To further characterize the mechanisms involved in the GW501516-or rosiglitazone-induced increase in SIRT1 expression, we investigated the effects of actinomycin D and cycloheximide. The induction of SIRT1 by specific PPAR ligands was reduced in the presence of actinomycin D or cycloheximide ( Figure 4e ). These results indicated that de novo synthesis of mRNA and protein(s) involved in the regulation of SIRT1 gene expression is essential for the PPAR-δ/γ-mediated induction of SIRT1 in RAW 264.7 cells. In line with these findings, GW501516 and rosiglitazone significantly induced SIRT1 promoter activity, suggesting that ligand-activated PPAR-δ and -γ upregulate SIRT1 expression at the transcriptional level (Figure 4f ).
SIRT1 is essential for inhibition of LPS-induced HMGB1
release by PPAR-δ and -γ. To further clarify the functional significance of SIRT1 upregulation by PPAR-δ and -γ, we assessed the impact of SIRT1 activity on the PPAR-δ/γ-mediated inhibition of LPS-induced HMGB1 release. Activation of SIRT1 by resveratrol inhibited HMGB1 release in RAW 264.7 cells treated with LPS (Figures 5a and c) . Furthermore, addition of resveratrol to GW501516-or rosiglitazone-treated cells potentiated the inhibitory effects of these PPAR ligands, suggesting that SIRT1 plays a modulatory role in the inhibition of HMGB1 release mediated by PPAR-δ and -γ. By contrast, inhibition of SIRT1 by sirtinol, an inhibitor of SIRT1, 21 counteracted the inhibitory effects of GW501516 or rosiglitazone on HMGB1 release (Figures 5b and d) . These results indicate that PPAR-δ and -γ regulate LPS-induced HMGB1 release by modulating SIRT1 activity.
Downregulation of SIRT1 abrogates the effects of PPAR-δ and -γ against HMGB1 release. To investigate the direct involvement of SIRT1 in the regulation of LPS-induced HMGB1 release, we examined the levels of released HMGB1 and SIRT1 protein in RAW 264.7 cells treated with LPS in the presence or absence of PPAR ligands. HMGB1 was released at high levels upon LPS treatment, whereas treatment with either GW501516 or rosiglitazone diminished LPS-induced HMGB1 release. On the other hand, endogenous expression of SIRT1 was almost completely suppressed in LPS-treated RAW 264.7 cells. This suppression, however, recovered in the presence of GW501516 or rosiglitazone, suggesting that SIRT1 has a role in the PPAR-δ/γ-mediated modulation of LPS-induced HMGB1 release (Figure 6a ).
To further clarify the role of SIRT1 in this process, we used siRNA to knockdown SIRT1 expression in RAW 264.7 cells (Supplementary Figure 3) . Both GW501516 and rosiglitazone inhibited LPS-induced release of HMGB1, whereas knockdown of SIRT1 reversed the effect of PPAR ligands on HMGB1 release in cells exposed to LPS (Figures 6b and c) . These results indicate that both PPAR-δ and -γ inhibit LPS-induced release of HMGB1 through SIRT1.
SIRT1-mediated deacetylation of HMGB1 is a critical factor in the PPAR-δ/γ-mediated inhibition of HMGB1 release. Because upregulation of SIRT1 by PPAR ligands affected the levels of LPS-induced HMGB1 acetylation, we investigated whether acetylated HMGB1 is a substrate for SIRT1. In RAW 264.7 cells overexpressing SIRT1, levels of LPS-induced acetylation and release of HMGB1 were significantly attenuated relative to those in cells transfected Figure 2 Acetylation is involved in the regulation of HMGB1 release. (a) RAW 264.7 cells incubated in serum-free medium for 24 h were pretreated with resveratrol or sirtinol for 1 h, and then stimulated with LPS for 6 h (for detection of acetyl-HMGB1) or 24 h (for detection of HMGB1 released). (b) Cells transfected with SIRT1 siRNA or control siRNA were grown for 38 h, after which they were incubated in serum-free medium for 24 h, and then stimulated with LPS for 6 h (for detection of acetyl-HMGB1) or 24 h (for detection of released HMGB1). Cell lysates were pulled down with anti-HMGB1 and immunoblotted with anti-acetyl-lysine to detect acetylated HMGB1. Each membrane was then stripped and re-probed for total HMGB1, as a loading control. For determination of released HMGB1, equal volumes of conditioned media were subjected to western blot analysis; Ponceau S staining was used as a loading control. Whole-cell lysates were subjected to Western blot analysis to determine the expression levels of HMGB1 (a) and SIRT1 (b). An image analyzer was used to quantitate band intensity, and the fold changes in the acetyl-HMGB1 to HMGB1 or HMGB1 to Ponceau S ratio are shown. The results are expressed as means ± S.E.M. (n = 3). **Po0.01, *Po0.05 compared with the untreated group; ## Po0.01, # Po0.05 compared with the LPS-treated group. Ponceau S staining or β-actin was used as a loading control with a control vector, and negatively correlated with levels of SIRT1 expression (Figure 7a ). To further clarify the role of acetylation in the HMGB1 release, we examined the effects of p300/CBP-associated factor (PCAF), which is responsible for HMGB1 acetylation in RAW 264.7 cells. 15 As shown in Figure 7b , HMGB1 acetylation was augmented by ectopic expression of PCAF, and this effect was potentiated in the presence of LPS. In line with levels of HMGB1 acetylation, the release of HMGB1 was increased in the presence of LPS or/and PCAF, indicating that acetylation is a critical factor in LPS-induced HMGB1 release. In addition, LPS-or PCAFdependent acetylation of HMGB1 was attenuated by ectopic expression of SIRT1 (Figure 7c) .
To further elucidate the role of SIRT1 in the deacetylation of HMGB1 in a gain-of-function study, we investigated the effects of overexpression of HMGB1 and SIRT1 in human embryonic kidney 293T (HEK293T) cells. Immunoprecipitation analysis revealed that acetylation of HMGB1 was increased over time, peaking 3 h after incubation with LPS and then declining to the basal level (Supplementary Figure 4) . The LPS-or PCAFinduced acetylation of HMGB1 was reversed by SIRT1 in cells expressing tagged proteins (Figures 8a and b) . Furthermore, we observed an increase in the levels of HMGB1 acetylation in mouse embryonic fibroblasts (MEFs) derived from SIRT1-knockout mice (SIRT1 − / − ) relative to those in wild-type mice (SIRT1 +/+ , Figure 8c ). However, the levels of HMGB1 acetylation in the SIRT1 − / − MEFs was reduced by the ectopic expression of SIRT1, supporting the idea that SIRT1 has a critical role in HMGB1 deacetylation (Figure 8d ). These results indicate that acetylated HMGB1 is an effective substrate for SIRT1.
Discussion
Activation of PPAR nuclear receptors and subsequent regulation of specific target genes elicit a complex series of inflammatory responses via transactivation or transrepression. Although multiple factors take part in the antiinflammatory activities of PPARs, very few of the actual effector genes involved in the effects of PPARs have been identified. Here, we demonstrated that activation of PPAR-δ and -γ by specific ligands, GW501516 and rosiglitazone, respectively, inhibits the LPS-primed release of HMGB1, a late mediator of lethality in endotoxic shock. 20 This inhibition is mediated by SIRT1, a class III deacetylase involved in inflammatory responses. [24] [25] [26] In RAW 264.7 cells treated with PPAR ligands, expression of SIRT1 mRNA was upregulated at the transcriptional level. Modulation of SIRT1 activity and Po0.01 compared with the group treated with LPS+GW501516 or rosiglitazone. Ponceau S staining or β-actin was used as a loading control expression by chemicals and siRNA abrogated the effects of PPAR-δ and -γ on HMGB1 release. Furthermore, HMGB1 acetylated by LPS or PCAF is a substrate for SIRT1, and deacetylation of HMGB1 by SIRT1 leads to a blockade of HMGB1 release. In line with these findings, HMGB1 acetylation levels were elevated in SIRT1 − / − MEFs. Activation of PPARs by specific ligands inhibited the LPSprimed release of HMGB1 in RAW 264.7 cells. Several PPAR isoforms were characterized for their roles in macrophages using specific ligands. Among these, rosiglitazone and GW501516, specific ligands of PPAR-γ and -δ, respectively, were superior to WY-14643, a specific ligand for PPAR-α, in the context of inhibition of LPS-induced HMGB1 release. This finding is in line with a previous study in which telmisartan, a non-selective ligand of PPAR-γ, attenuated post-ischemic injury by partially inhibiting the inflammatory reaction via a PPAR-γ-dependent inhibition of HMGB1 release. 32 On the other hand, a different line of study indicated that the PPAR-γ agonist troglitazone inhibits HMGB1 expression in endothelial cells. 33 This is in contrast to our findings reported here, which − / − MEFs were transfected with empty vector (pcDNA3.1-Myc) or pcDNA3.1-Myc-SIRT1 and incubated for 48 h, after which the cells were harvested and subjected to immunoprecipitation with anti-HMGB1 antibody. Acetylated HMGB1 or total HMGB1 and SIRT1 were detected by western blot analysis. β-actin was used as a loading control indicate that ligand-activated PPARs inhibited LPS-induced release of HMGB1, whereas expression levels of intracellular HMGB1 were unaffected by PPARs in RAW 264.7 cells treated with LPS. Although no conclusive data are available at present, it is gradually becoming clearer that in macrophages treated with LPS, PPARs participate in the inflammatory responses by regulating the activities of HMGB1.
Posttranslational modification of HMGB1 appears to be a critical step in the regulation of the release of this protein during inflammatory responses. 15, 16 In line with previous studies, ligand-activated PPAR-δ and -γ suppressed LPSinduced HMGB1 acetylation and reduced the release of HMGB1. This effect of PPAR-δ and -γ on HMGB1 release was correlated with the levels of SIRT1, suggesting a mechanism in which SIRT1 deacetylates HMGB1, leading to the inhibition of HMGB1 release. This finding is consistent with previous studies demonstrating that SIRT1 has an important role in modulating the development and progression of inflammation by deacetylating histones and critical transcription factors such as NF-κB and AP-1, leading to transcriptional repression of various inflammation-related genes. 24, 25, 34 Thus, SIRT1 has emerged as a critical regulator that suppresses the function of immune cells; 35, 36 such findings provide a rationale for the use of SIRT1 activators in therapy directed against inflammatory diseases. Indeed, several lines of evidence indicate that a reduction in the level of SIRT1 is closely associated with many inflammatory diseases. 21 Because HMGB1 is extensively modified (hyperacetylated, in LPSactivated monocytes) and released, leading to its participation in the inflammatory response, it may be possible to inhibit inflammatory reactions by increasing SIRT1 levels through activation of PPAR-δ or -γ.
Upregulation of SIRT1 expression by PPAR-γ and -δ is a key event in the blockade of LPS-induced HMGB1 release. SIRT1, a NAD + -dependent class III protein deacetylase, modulates a variety of cellular processes, including aging, inflammation, stress resistance, and energy metabolism via its deacetylase activity. [22] [23] [24] [25] [26] In mammalian cells, the transcriptional regulation of SIRT1 is complex and involves energy metabolism-related pathways, such as caloric restriction. 37, 38 Transcription factors such as BRCA1, E2F1, HIC1, and TLX also have roles in the regulation of SIRT1 expression. [39] [40] [41] [42] However, the full picture of SIRT1 transcriptional regulation has not been fully elucidated. PPAR-δ, but not PPAR-α or -γ, was originally shown to promote the expression of SIRT1 in human hepatocyte-derived cells. 30 In that case, SIRT1 expression is mediated by a non-conventional signaling mechanism in which Sp1, but not PPRE, has a central role. Induction of SIRT1 by GW501516, a specific ligand of PPAR-δ, was also demonstrated in our previous study. 43 The effects of GW501516 on SIRT1 may contribute to the functions of PPAR-δ, such as its anti-senescence activity, by regulating the generation of reactive oxygen species. However, transcription of SIRT1 is inhibited by ligand-activated PPAR-γ in senescent cells. 44 Inhibition of SIRT1 by PPAR-γ occurs in the context of a negative-feedback self-regulatory loop, mediated by acetylation of PPAR-γ, through direct interactions with both proteins. Although the roles of PPAR-δ and -γ in SIRT1 expression are controversial, the data presented here clearly demonstrate that ligand-activated PPAR-δ and -γ upregulate SIRT1 expression at the transcriptional level.
Damaged cells activate innate immunity and recruit inflammatory cells by releasing danger signals known as damage-associated molecular patterns (DAMPs). HMGB1, a DAMP molecule, is actively secreted by immune cells such as macrophages, natural killer cells, and dendritic cells. 9, 45 A number of mechanisms have been postulated regarding the regulation of HMGB1 release in immune cells, [15] [16] [17] [18] of which the most feasible appears to be acetylation of HMGB1 on lysine residues in response to interleukin-1β, TNF-α, and LPS. 15, 16 In this study, we identified acetylation of HMGB1 as a key aspect of the regulation of its active release from RAW 264.7 cells treated with LPS. We also determined the influence of the SIRT1 deacetylase on the levels of HMGB1 acetylation. To our knowledge, this study is the first report to demonstrate that the upregulation of SIRT1 by PPAR-δ and -γ modulates HMGB1 release by deacetylating HMGB1 previously acetylated in response to LPS. These novel observations have important implications regarding our understanding of the molecular mechanisms underlying the antiinflammatory effect of PPAR-δ and -γ, as well as the transcriptional regulation of SIRT1. In light of these findings, it is possible that reinforcement of SIRT1 activity by PPARs in macrophages represents a novel effective strategy for preventing or treating inflammatory disease. Polyclonal anti-hemagglutinin antibody was obtained from Cell Signaling (Beverly, MA, USA). Polyclonal antibodies specific for PPAR-γ, SIRT1, and c-Myc, and horseradish peroxidase-conjugated IgG, were supplied by Santa Cruz Biotechnology (Dallas, TX, USA). Monoclonal antibodies specific for HMGB1 and PPAR-δ were purchased from Epitomics (Burlingame, CA, USA). The luciferase assay system was obtained from Promega (Madison, WI, USA). Other reagents were of the highest grade available.
Cell culture. RAW 264.7 macrophage cells and HEK293T were obtained from the American Type Culture Collection (Manassas, VA, USA). MEFs derived from wild-type or SIRT1-knockout mice were kindly provided by Dr. Richard Allsopp (Burns School of Medicine, University of Hawaii, Honolulu, HI, USA). Cells were maintained in Dulbecco's modified Eagle's medium containing 100 U/ml penicillin and 100 μg/ml streptomycin, supplemented with 10% heat-inactivated fetal bovine serum, at 37°C under an atmosphere of 95% air and 5% CO 2 .
Gene silencing with siRNA. Cells were seeded in 60 mm culture dishes 18-24 h prior to transfection. Cells were transfected with 100 nM control siRNA (Ambion, Austin, TX, USA), 100 nM rat PPAR-δ siRNA (Ambion), rat PPAR-γ (Ambion), or 100 nM SIRT1 siRNA designed against nucleotides (5ʹ-TGA AGT GCC TCA GAT ATT A-3ʹ and 5ʹ-TAA TAT CTG AGG CAC TTC A-3ʹ) of the rat SIRT1 mRNA sequence (Bioneer, Daejeon, Korea) using SuperFect (Qiagen, Valencia, CA, USA) in serum-containing medium. Following incubation for 6 h, the transfection medium was replaced with fresh medium, and the cells were incubated for an additional 38 h, at which point they were treated with the indicated reagents for the indicated times. The effects of gene silencing were determined by Western blot analysis.
Western blot analysis. Cells treated with the indicated reagents were washed with ice-cold phosphate-buffered saline (PBS) and lysed in PRO-PREP
